Pulmonary Artery Hypertension/Embolism

Background: Pulmonary arterial hypertension (PAH) is a complex cardiovascular disorder characterized by a sustained increase in pulmonary arterial pressure (PAP) driven by vascular remodeling, which leads to an increased right ventricular (RV) afterload and subsequent RV hypertrophy (RVH). Ultimately, it causes RV dysfunction.

Pulmonary embolism (PE) is when a blood clot (thrombus) becomes lodged in an artery in the lung and blocks blood flow to the lung.

Model: GSPEA/Monocrotaline induced PE/PAH

Standard study duration: 4-8weeks

Clinical endpoint: CT/eCT, ultrasound, respiratory rate, heart rate, SpO2…

Features: Human-like disease, same embolization mechanism, reversible/irreversible model, clinical endpoints

For more information about these models, please contact Mr. James Song, mailto:james.song@prisysbiotech.com